This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by Assaf-Harofeh Medical Center.
Recruitment status was:  Recruiting
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: December 7, 2006
Last updated: June 17, 2008
Last verified: June 2008
In latest literature more evidence is available about the positive effect of alpha blocker on stone expulsion from the ureter. Patients benefit from less pain and shortening time to stone expulsion. Our study is design to evaluate whether alfuzosin improves the stone free out come following SWL.

Condition Intervention Phase
Urolithiasis Nephrolithiasis Ureterolithiasis Drug: Alpha blocker-alfuzosin Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Prospective Randomized Placebo Controlled Blinded Study to Evaluate the Efficacy of Alfuzosin (Alpha Blocker) on the Success Rates Following SWL.

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:

Primary Outcome Measures:
  • use of pain control medication stone free rates [ Time Frame: 3 months ]
  • pain visual analogue scale [ Time Frame: 3 month ]
  • side effects [ Time Frame: 3 months ]
  • stone free rate [ Time Frame: 3 months ]
  • time to stone free status [ Time Frame: 3 months ]
  • need for secondary procedures [ Time Frame: 3 months ]
  • auxiliary procedures [ Time Frame: 3 months ]

Estimated Enrollment: 150
Study Start Date: December 2006
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
double blind placebo control
Drug: Alpha blocker-alfuzosin
P.O. alfuzosin 10 mg once a day
Placebo Comparator: 2
placebo control blinded arm
Drug: placebo
placebo once a day for 3 months or stone free

Detailed Description:

All patients undergoing SWL are included in study. Exclusion criteria: Patient with radio-lucent stone, patients treated with calcium channel blockers, alpha blockers, steroids, patients with contraindication to alpha blocker treatment, postural hypotension patents with abnormal liver function tests.

Patient will be recruited to the study prospectively. Following signature on inform consent patients will be randomized into 2 groups. One group will be treated with alfuzosin 10mg a day and the control group with placebo. Treatment will be initiated following the lithotripsy treatment.

Parameters for investigation includes: demographic and personal data, stone size and location (obtained by CT or KUB), pain control medication and visual analogue scale assessment of pain, side effects, clinical squeals, stone free out come. Follow up evaluation will be at 1 week, 1 month, and 3 months post treatment. Success will be defined following CT evaluation at 3 months. Treatment ends at stone free achievement or at 3 months.

Endpoints:Stone free rate, time to stone free, side effect.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • patients undergoing shock wave lithotripsy treatment for urolithiasis.

Exclusion Criteria:

  • patients with abnormal liver function, postural hypotension, alpha-blocker treatment, sensitivity to alpha-blockers, radio-lucent stone, calcium channel blocker treatment, steroids treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00409227

Contact: yoram I siegel, MD 972-577-345408

Endourology unit Urology department Assaf Harofeh MC Recruiting
Zerifin, Israel, 40700
Contact: yoram i siegel, MD    972-577-345408   
Principal Investigator: yoram i siegel, MD         
Sub-Investigator: yaniv shilo, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Principal Investigator: yoram I siegel, MD Endourology unit Urology department Assaf harofeh MC.
  More Information

Responsible Party: Yoram I Siegel MD, Assaf Harofeh MC Identifier: NCT00409227     History of Changes
Other Study ID Numbers: 165/05
Study First Received: December 7, 2006
Last Updated: June 17, 2008

Keywords provided by Assaf-Harofeh Medical Center:
stone disease

Additional relevant MeSH terms:
Kidney Calculi
Ureteral Calculi
Kidney Diseases
Urologic Diseases
Urinary Calculi
Pathological Conditions, Anatomical
Ureteral Diseases
Adrenergic alpha-Antagonists
Adrenergic alpha-1 Receptor Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on September 19, 2017